Clinical Efficacy of Bazhen Huaji Decoction Combined with Camrelizumab in the Treatment of Advanced Esophageal Cancer
Objective:To investigate the clinical efficacy of Bazhen Huaji Decoction combined with camrelizumab in the treatment of advanced esophageal cancer.Methods:A retrospective analysis was conducted on the clinical data of 104 patients with advanced esophageal cancer who were treated between May 2022 and July 2023 at Hefei Cancer Hospital of the Chinese Academy of Sciences and the West District of Anhui Provincial Hospital of Traditional Chinese Medicine.Patients were divided into groups according to treatment method:52 patients receiving camrelizumab alone were classified as the routine group,and 52 patients receiving Bazhen Huaji Decoction combined with camrelizumab were classified as the combination group.The groups were compared in terms of Traditional Chinese Medicine(TCM)syndrome scores,serum levels of programmed death receptor 1(PD-1),programmed death ligand 1(PD-L1),squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA),Karnofsky Performance Status(KPS)scores,T-cell subsets CD3+,CD4+,CD4+/CD8+,dendritic cells(DC),clinical efficacy,and incidence of adverse reactions.Results:After treatment,TCM syndrome scores in the combination group were lower than those in the routine group(P＜0.01);PD-1 and PD-L1 levels in the combination group were also lower(P＜0.01);SCC-Ag and CEA levels in the combination group were lower than in the routine group(P＜0.05);KPS scores were higher in the combination group(P＜0.01);CD3+,CD4+,CD4+/CD8+,and DC levels in the combination group were higher than in the routine group(P＜0.01);and the overall effective rate of treatment in the combination group was higher than that in the routine group(P＜0.05).There was no statistically significant difference in the total incidence of grade 1-2 adverse reactions between the groups(P＞0.05).Conclusion:Bazhen Huaji Decoction combined with camrelizumab can improve serum indicators and tumor marker levels in patients with advanced esophageal cancer,reduce TCM syndrome scores,enhance immune function,improve clinical efficacy,and prolong patient survival,with high safety.
万方数据
维普
